Authors
Latest:
Dr. Dowdy on the Association of Molecular Subtypes and Responses to Bevacizumab in Ovarian CancerSean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.
Latest:
Ovarian Cancer Subtypes May Predict Response to BevacizumabSean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
Latest:
Dr. Grimm on the Brain Cancer Predictive Marker MGMTDr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer
Latest:
Coping With Burnout? Tips on Handling This Occupational HazardBurnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.
Latest:
Dr. Szeja on Adjuvant Radiation Therapy After Lumpectomy in Elderly Patients With TNBCSean Szeja, MD, radiation oncologist, University of Texas Medical Branch, discusses outcomes associated with adjuvant radiation therapy following lumpectomy for elderly patients with triple-negative breast cancer.
Latest:
Different Faces of a Career in OncologyAt various stages of our lives, most of us experience situations or events that help us to mature and may lead to decisions that affect our futures. Two such events in my life forged my career choice as a communitybased oncologist.
Latest:
Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community PracticeNon-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.
Latest:
Dr. Stuart on Risks of Phase I Liver Dysfunction StudiesSelena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.
Latest:
Challenges in the Treatment of Patients With MCLSelina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses challenges in the treatment of patients with mantle cell lymphoma (MCL).
Latest:
Dr. Giralt on the Rationale of the Karmma-3 trial of Ide-cel in R/R MyelomaSergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.
Latest:
VOD: Ensuring Best OutcomesExperts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Berk on Immunotherapy Options for Patients With Colon CancerSeth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.
Latest:
Dr. Pollack on the Future Treatment Landscape for SarcomaSeth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.
Latest:
Dr. Choi on Considering Factors for RT in Prostate CancerSeungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple MyelomaShaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.
Latest:
Clinical Pearls and Future Directions in AL AmyloidosisDr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.
Latest:
There's No Place Like a Medical Home: Premier Medical Group Focuses on Full-scale Patient-Centered CareIt's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.
Latest:
Novel Radiation Oncology Research Makes Population Health Strategies SmarterFor the past 5 years, Montefiore has been a leading Pioneer Accountable Care Organization (ACO) in CMS’ ACO program, which aims to improve the quality of care for Medicare beneficiaries while identifying ways to save healthcare dollars.
Latest:
Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple MyelomaSham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Wingo on the Evolution of Surgery in Endometrial CancerShana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the evolution of surgery in endometrial cancer.
Latest:
Dr. Meehan on Importance of IHC Testing in MelanomaShane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.
Latest:
Surgery in Oncology Is Not Always a Simple DecisionThe personalization of cancer care is more elaborately expressed in multidisciplinary tumor conferences and clinical trials.
